Delivery Order SPE2DB22D3501-SPE2DB25FXK49
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SPIKEVAX 2024-25 vaccine (12 years and up), 0.5ml syringes, with a ceiling value of $5,887.40. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,431.78 on June 18, 2025, for the supply of Spikevax 2024-25 vaccine (12 years and older) in 0.5 mL syringes. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 11, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,672.76 to AmerisourceBergen Drug Corp for Spikevax 2025-26 vaccine doses (0.5mL syringes for ages 12 and up) on September 15, 2025, with completion expected by October 6, 2025. This firm fixed-price, non-set-aside contract represents a discrete purchase under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be supplied from the contractor's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $1,177.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for Spikevax 2024-25 vaccine (12 years and up) in 0.5ml syringes, with an ultimate completion date of October 3, 2025. This is a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Spikevax 2024-25 vaccine (12 years and up) in 0.5ML syringes, with a ceiling value of $1,177.48 and completion date of September 22, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value transaction reflecting the agency's procurement of influenza vaccines to support military healthcare operations. The order was placed under...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order with a Firm Fixed Price of $1,431.78 for the SPIKEVAX 2024-25 (12Y UP) SYRG 0.5ML vaccine product. The contract has an ultimate completion date of July 29, 2025 and was awarded on July 8, 2025 by the Defense Logistics Agency (DLA), a defense agency. The contract is not set aside and is an open competition award. Amerisourcebergen Drug Corp is the prime contractor for this...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,416.00, is for the procurement of SPIKEVAX 2024-25 (12Y UP) SYRG 0.5ML, which are likely COVID-19 vaccine syringes. The contract has an ultimate completion date of February 4, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a $4,254 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for SPIKEVAX COVID-19 vaccine syringes for individuals 12 years of age and older, with a completion date of January 17, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,334.68 firm-fixed-price delivery order is for the supply of SPIKEVAX 2024-25 (12Y UP) SYRG 0.5ML vaccines, with an ultimate completion date of November 15, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award, valued at $1,418.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of SPIKEVAX 2024-25 (12Y UP) SYRG 0.5ML, a vaccine product, with a completion date of December 12, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXK49Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,336.38 on September 18, 2025, for SPIKEVAX 2025-26 vaccine doses (12 years and up) in 0.5mL syringes. The contract carries a firm fixed price and is scheduled for completion by October 9, 2025. This non-set-aside award is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, reflecting the company's role as a critical pharmaceutical distributor supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive capability in fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, consistently competing successfully for open-market procurements with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 9/18/25 |